These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 36071221)

  • 1. Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals.
    Ebenau JL; Visser D; Verfaillie SCJ; Timmers T; van Leeuwenstijn MSSA; Kate MT; Windhorst AD; Barkhof F; Scheltens P; Prins ND; Boellaard R; van der Flier WM; van Berckel BNM
    Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):410-422. PubMed ID: 36071221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer's disease.
    Visser D; Wolters EE; Verfaillie SCJ; Coomans EM; Timmers T; Tuncel H; Reimand J; Boellaard R; Windhorst AD; Scheltens P; van der Flier WM; Ossenkoppele R; van Berckel BNM
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3165-3175. PubMed ID: 32462397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project.
    Timmers T; Ossenkoppele R; Verfaillie SCJ; van der Weijden CWJ; Slot RER; Wesselman LMP; Windhorst AD; Wolters EE; Yaqub M; Prins ND; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BNM
    Neurobiol Aging; 2019 Jul; 79():50-58. PubMed ID: 31026622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer's disease.
    Visser D; Verfaillie SCJ; Wolters EE; Coomans EM; Timmers T; Tuncel H; Boellaard R; Golla SSV; Windhorst AD; Scheltens P; van der Flier WM; van Berckel BNM; Ossenkoppele R
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1951-1963. PubMed ID: 34997294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau pathology as determinant of changes in atrophy and cerebral blood flow: a multi-modal longitudinal imaging study.
    Visser D; Verfaillie SCJ; Bosch I; Brouwer I; Tuncel H; Coomans EM; Rikken RM; Mastenbroek SE; Golla SSV; Barkhof F; van de Giessen E; van Berckel BNM; van der Flier WM; Ossenkoppele R
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2409-2419. PubMed ID: 36976303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Grey zone amyloid burden affects memory function: the SCIENCe project.
    Ebenau JL; Verfaillie SCJ; van den Bosch KA; Timmers T; Wesselman LMP; van Leeuwenstijn M; Tuncel H; Golla SVS; Yaqub MM; Windhorst AD; Prins ND; Barkhof F; Scheltens P; van der Flier WM; van Berckel BNM
    Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):747-756. PubMed ID: 32888039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional [
    Wolters EE; Ossenkoppele R; Verfaillie SCJ; Coomans EM; Timmers T; Visser D; Tuncel H; Golla SSV; Windhorst AD; Boellaard R; van der Flier WM; Teunissen CE; Scheltens P; van Berckel BNM
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2866-2878. PubMed ID: 32291510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
    Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
    Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
    Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between quantitative [
    Timmers T; Ossenkoppele R; Wolters EE; Verfaillie SCJ; Visser D; Golla SSV; Barkhof F; Scheltens P; Boellaard R; van der Flier WM; van Berckel BNM
    Alzheimers Res Ther; 2019 Jul; 11(1):60. PubMed ID: 31272512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study.
    Wolters EE; van de Beek M; Ossenkoppele R; Golla SSV; Verfaillie SCJ; Coomans EM; Timmers T; Visser D; Tuncel H; Barkhof F; Boellaard R; Windhorst AD; van der Flier WM; Scheltens P; Lemstra AW; van Berckel BNM
    Neuroimage Clin; 2020; 28():102504. PubMed ID: 33395993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
    Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
    Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies.
    Arenaza-Urquijo EM; Przybelski SA; Lesnick TL; Graff-Radford J; Machulda MM; Knopman DS; Schwarz CG; Lowe VJ; Mielke MM; Petersen RC; Jack CR; Vemuri P
    Brain; 2019 Apr; 142(4):1134-1147. PubMed ID: 30851100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
    Yew B; Nation DA;
    Brain; 2017 Jul; 140(7):1987-2001. PubMed ID: 28575149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology.
    Okada H; Ouchi Y; Ogawa M; Futatsubashi M; Saito Y; Yoshikawa E; Terada T; Oboshi Y; Tsukada H; Ueki T; Watanabe M; Yamashita T; Magata Y
    Brain; 2013 Oct; 136(Pt 10):3004-17. PubMed ID: 23975517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebral Microhemorrhage at MRI in Mild Cognitive Impairment and Early Alzheimer Disease: Association with Tau and Amyloid β at PET Imaging.
    Rauchmann BS; Ghaseminejad F; Mekala S; Perneczky R;
    Radiology; 2020 Jul; 296(1):134-142. PubMed ID: 32368960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of T1-weighted/T2-weighted magnetic resonance ratio to elucidate changes due to amyloid β accumulation in cognitively normal subjects.
    Yasuno F; Kazui H; Morita N; Kajimoto K; Ihara M; Taguchi A; Yamamoto A; Matsuoka K; Takahashi M; Nakagawara J; Iida H; Kishimoto T; Nagatsuka K
    Neuroimage Clin; 2017; 13():209-214. PubMed ID: 28003959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.